Published August 17, 2026Updated October 15, 2026

Ozempic and Gallbladder Issues: What the Research Actually Shows

The elevated risk of gallbladder disease on GLP-1 drugs: what the JAMA meta-analysis found, why it happens, and who's at higher risk.

By Ruth Calder, Enforcement Editor

Our methodology sets out how these guides get researched and kept current.

Looking for a provider? Our 2026 comparison of the leading GLP-1 telehealth sellers is a click away.

Best GLP-1 Providers →

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Gallbladder problems are one of the more serious but less discussed side effects of GLP-1 drugs. Pooling 76 randomized trials, the 2022 JAMA Internal Medicine meta-analysis found a 37% higher risk of gallbladder and biliary disease with GLP-1 agonists, and roughly double the risk in trials of weight loss. That is no reason to panic, because the absolute risk stays low, but it is worth understanding before treatment starts, particularly if gallstones run in your history or your family's.

This article covers what the research shows, why GLP-1 drugs stress the gallbladder, the specific symptoms to watch for, and what to do if you have a history of gallbladder issues. Every claim is sourced to primary clinical literature or the FDA label.

Key Takeaways

  • GLP-1 drugs raise the risk of gallbladder disease by about 37% overall, and roughly double it in weight-loss trials (JAMA Internal Medicine 2022 meta-analysis of 76 trials).
  • Absolute risk is still low: in Wegovy's weight-loss trials, gallstones were reported in 1.6% of patients vs 0.7% on placebo.
  • Higher doses and longer durations carry higher risk.
  • Two mechanisms: rapid weight loss (itself a gallstone risk factor) plus reduced gallbladder contractility from GLP-1 signaling.
  • Symptoms: right-upper-quadrant pain, nausea, vomiting, fever, jaundice. Pain after fatty meals is classic.
  • Highest risk patients: history of gallstones, female, age 40+, rapid weight loss, obesity at baseline.
  • FDA labels list gallbladder disease as a warning on Wegovy, Zepbound, and Ozempic.

What the JAMA Meta-Analysis Found

The definitive paper on this question is He et al., published in JAMA Internal Medicine in 2022. The researchers pooled data from 76 randomized controlled trials with over 100,000 participants, comparing GLP-1 receptor agonists (including semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide) against placebo or non-GLP-1 drugs.

Headline findings

  • Overall risk ratio: 1.37 for any biliary/gallbladder disease (37% relative increase)
  • Cholelithiasis (gallstones) specifically: risk ratio 1.27
  • Cholecystitis (gallbladder inflammation): risk ratio 1.36
  • Biliary disease overall: risk ratio 1.55
  • Higher doses associated with higher risk: risk ratio 1.56 at higher doses vs 0.99 at lower doses.
  • Weight-loss trials showed the strongest signal: risk ratio 2.29 in the 13 trials for weight loss, vs 1.27 where the trials were for type 2 diabetes or other diseases.
  • Longer treatment duration associated with higher risk: risk ratio 1.40 with longer use vs 0.79 with shorter use.

Absolute numbers

Relative risk matters less than absolute risk. The meta-analysis abstract reports relative risks only, but the Wegovy label gives absolute rates from its weight-loss trials in adults:

  • Gallstones (cholelithiasis): 1.6% on Wegovy injection vs 0.7% on placebo
  • Gallbladder inflammation (cholecystitis): 0.6% on Wegovy injection vs 0.2% on placebo
  • Excess risk: roughly 1 additional case of gallstones per 100 treated patients over the trials

That's meaningful but not alarming. For context, being female and over 40 carries a baseline gallstone risk of roughly 10–15% over a lifetime.

Why GLP-1 Drugs Affect the Gallbladder

Two independent mechanisms explain the increased risk, and they stack.

1. Rapid Weight Loss Itself Causes Gallstones

This is well-established outside of GLP-1 drugs. Any rapid weight loss, whether from bariatric surgery, very-low-calorie diets, or pharmacologic weight loss, increases gallstone risk. When you lose fat rapidly, your liver dumps extra cholesterol into bile, and your gallbladder empties less frequently (because you're eating less). Supersaturated, stagnant bile is the recipe for gallstones.

The NIDDK gallstones overview notes that losing weight very quickly may raise the chance of forming gallstones.

GLP-1 drugs produce large, sustained weight loss over many months: in STEP 1, patients lost ~15% of body weight in 68 weeks. The Wegovy label notes that substantial or rapid weight loss can increase gallstone risk, but that gallbladder disease was still more common on Wegovy than on placebo after accounting for the degree of weight loss.

2. Direct GLP-1 Effect on Gallbladder Motility

GLP-1 receptors exist in the gallbladder itself. Chronic GLP-1 activation appears to slow gallbladder emptying, the same mechanism that slows stomach emptying. When the gallbladder empties more slowly, bile sits in it longer and is more likely to precipitate into stones.

This second mechanism is additive to the weight-loss mechanism. It's why GLP-1 drugs appear to carry more gallbladder risk than other weight-loss methods at the same rate of weight loss.

Symptoms to Watch For

The classic symptoms of gallbladder disease are distinctive, and knowing them helps you recognize them immediately:

Symptoms to Watch For
SymptomDescription
Right-upper-quadrant painSharp and gripping, beneath the right ribs, and it commonly travels to the right shoulder or the back
Pain after fatty mealsClassic gallbladder pain is triggered 1–2 hours after eating fatty or fried food
Nausea and vomitingSevere, often without relief from usual remedies
Fever and chillsSuggests cholecystitis (inflammation), not just stones
JaundiceYellowing of skin/eyes suggests a stone blocking the common bile duct — medical emergency
Dark urine, pale stoolsAlso suggests bile duct obstruction

Mild gallbladder pain can sometimes be mistaken for typical GLP-1 nausea. The key differentiator: GLP-1 nausea usually doesn't involve localized right-upper-quadrant pain, and it improves over 1–3 days. Gallbladder pain is sharp, localized, and worsens over hours.

When to seek emergency care:

  • Severe, constant abdominal pain lasting more than 2 hours
  • Pain plus fever or chills
  • Jaundice (yellow skin or eyes)
  • Pain with inability to keep fluids down

Who's at Higher Risk?

Some patients carry meaningfully higher gallbladder risk on GLP-1 drugs. You should discuss these with your prescriber before starting.

Higher baseline risk

  • History of gallstones or prior cholecystectomy (gallbladder removal is not a contraindication, but it does raise the risk of common bile duct stones)
  • Female sex: women have 2–3x baseline gallstone risk vs men
  • Age 40+: gallstone incidence rises sharply after 40
  • Obesity at baseline: BMI 30+ already carries elevated risk
  • Family history of gallstones
  • Certain ethnic backgrounds: Native American, Mexican American, and Scandinavian populations have elevated baseline risk
  • Diabetes
  • Estrogen exposure (including oral contraceptives and HRT)

Modifiable risk factors

  • Rapid weight loss: slower titration and slower weight loss reduces but doesn't eliminate risk
  • Very low-fat diet: paradoxically, very-low-fat diets can worsen gallbladder stasis. A small amount of dietary fat (20–30 g/day) helps trigger normal gallbladder contraction.
  • Dehydration: adequate fluid intake supports bile flow

What the FDA Labels Say

The FDA labels for Wegovy, Zepbound, and Ozempic all include gallbladder disease as a warning. From the Wegovy label:

> "Treatment with WEGOVY is associated with an increased occurrence of cholelithiasis and cholecystitis. … In randomized clinical trials in adults for weight reduction, cholelithiasis was reported by 1.6% of WEGOVY injection-treated patients and 0.7% of placebo injection-treated patients, and by 2.5% of WEGOVY tablet-treated patients and 1% of placebo tablet-treated patients. Cholecystitis was reported by 0.6% of WEGOVY injection-treated adult patients and 0.2% of placebo-treated patients."

When gallstones are suspected, the label calls for gallbladder testing and clinical follow-up.

What to Do If You Have a History of Gallstones

A history of gallstones isn't an absolute contraindication to GLP-1 drugs, but it warrants a real conversation with your prescriber. Considerations:

  1. Have you had a cholecystectomy? If your gallbladder has already been removed, the risk picture shifts: you can't develop new gallbladder stones, but stones can still turn up in the bile ducts (choledocholithiasis), which is more serious.
  1. When were your stones diagnosed? Active untreated stones are a higher concern than a prior episode that resolved with diet changes.
  1. Is a slower titration reasonable? Some prescribers extend titration steps (6–8 weeks instead of 4) for patients with gallbladder risk factors, to slow the rate of weight loss.
  1. Is ursodiol an option? Ursodeoxycholic acid (ursodiol) is an old bile acid supplement sometimes prescribed during rapid weight loss (including after bariatric surgery) to reduce gallstone formation. Some prescribers consider it for high-risk GLP-1 patients, though it's off-label for this use.

Do's and Don'ts

Do:

  • Tell your prescriber about any history of gallstones or gallbladder surgery before starting
  • Report right-upper-quadrant pain immediately, especially if it follows fatty meals
  • Keep some dietary fat in your meals (not zero-fat)
  • Stay well hydrated throughout titration
  • Consider slower titration if you have risk factors
  • Know the emergency symptoms (fever, jaundice, severe constant pain)

Don't:

  • Ignore persistent right-upper-quadrant pain as "just GLP-1 nausea"
  • Go on a zero-fat diet while on GLP-1 drugs
  • Rush titration to maximum dose without talking to your prescriber
  • Stop the drug abruptly if symptoms develop; call your prescriber first
  • Assume your risk is zero just because you've never had gallbladder symptoms

Pros and Cons of Continuing GLP-1s with Gallbladder Risk

Arguments for continuing:

  • Absolute risk is still low (about 1 extra case of gallstones per 100 patients in Wegovy's trials)
  • The metabolic benefits of weight loss include long-term gallbladder health
  • Slower titration and ursodiol can mitigate risk
  • Many patients complete multi-year GLP-1 courses without any gallbladder event

Arguments for caution:

  • Active symptoms or acute cholecystitis require immediate treatment and drug discontinuation
  • A second episode raises the odds of needing cholecystectomy
  • Bile duct stones after prior cholecystectomy are a serious concern

Bottom Line

GLP-1 drugs modestly but meaningfully increase the risk of gallbladder disease: in Wegovy's weight-loss trials, about 1 extra case of gallstones per 100 patients. In absolute terms the added risk is small, though it is real. For anyone without active gallbladder disease, the cardiometabolic benefit of sustained weight loss almost always outweighs it. For patients with a history of gallstones, a slower titration, careful symptom monitoring, and open communication with your prescriber are the right approach.

If you develop severe right-upper-quadrant pain, fever, or jaundice, go to the emergency department; these are not symptoms to manage at home. For the broader side-effect picture, see our managing semaglutide side effects guide. For questions about whether to continue the drug after a gallbladder event, read what happens after you stop Ozempic or Wegovy, because the decision to stop is rarely straightforward.

If you're still selecting a provider and want one that offers strong clinical support through side-effect events, see our best GLP-1 providers ranking.

Sources & methodology — as of October 2026
  1. 1.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  2. 2.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  3. 3.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  4. 4.FDA Adverse Event Monitoring System (AEMS) Public Dashboard (formerly FAERS)— U.S. Food & Drug Administration.
  5. 5.SUSTAIN-6 Trial — Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (Marso SP et al.)— New England Journal of Medicine.PMID: 27633186.

Ready to compare GLP-1 providers?

Trust, support, availability, the medications carried and what they cost — we rank every major telehealth seller on all five, and refresh it each quarter. Nothing padded.

Best GLP-1 Providers →

Read our methodology · affiliate disclosure · about us